Peripheral Vascular Devices Market Size, Share & Trends Analysis Report By Type (Peripheral Stents, PTA Balloons, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices), By Region, And Segment Forecasts, 2024 - 2030

Peripheral Vascular Devices Market Size, Share & Trends Analysis Report By Type (Peripheral Stents, PTA Balloons, Catheters, Endovascular Aneurysm Repair Stent Grafts, Plaque Modification Devices), By Region, And Segment Forecasts, 2024 - 2030


Peripheral Vascular Devices Market Growth & Trends

The global peripheral vascular devices market size is expected to reach USD 14,839.0 million by 2030 and is projected to grow at a CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. One of the main factors propelling the market growth is the rising prevalence of venous disorders or Chronic Venous Insufficiency (CVI). Its adoption is also being accelerated by the growing elderly population and the rising demand for minimally invasive endovascular operations, novel product launch, mergers, and collaborations by the key market players for business expansion are some of the factors that boosts the market growth.

IVC filters, hemodynamic flow alteration, EVAR stent-grafts, angiography catheters, and plague modification devices are some of the devices utilized in peripheral endovascular and coronary procedures, as well as for treating peripheral arterial or coronary arterial disease. These tools are used during surgery to reduce patient interference with the least amount of disruption. The market demand for peripheral vascular devices is significantly influenced by the rising need for less invasive procedures for the treatment of vascular disease. Patients are more likely to prefer minimally invasive procedures since they speed up or aid the healing process, lessen patient trauma, and necessitate shorter hospital stays.

For instance, in February 2020, HonorHealth, a premier healthcare provider in the Valley that provides care to 1.6 million residents of the greater Phoenix area, announced today that its Cardiovascular Center of Excellence has made a significant advancement in the treatment of peripheral arterial disease (PAD). It is a common cardiovascular condition that affects more than 10 million people in the country. A patient with a completely blocked femoral artery underwent surgery as part of a DETOUR II clinical trial. The treatment was a percutaneous (skin puncture) bypass. Up to 200 patients were accepted for the research, which might result in FDA approval for the treatment. Without cutting open or making incisions in the leg, a peripheral percutaneous bypass procedure was conducted on a patient with advanced PAD. This makes such surgery minimal invasive and possibly riskier than the conventional approach. The DETOUR II treatment involved the use of stent grafts that run via the femoral vein, bypassing the damaged section of the femoral artery and, in essence, providing a bypass so that blood can flow freely to the patient's lower limb once more.

Moreover, minimally invasive procedures tend to minimize the post-surgery complications and reduce the mortality rates. Some of these procedures including balloon angioplasty, drug-eluting technologies, excisional atherectomy or laser ablation are significant in improving quality of life. As a result, these advantages are anticipated to raise market demand for peripheral vascular devices.

Increased patient awareness and healthcare spending, as well as higher acceptance rates of minimally invasive surgery, all contribute to its significant market share. In addition, the industry as a whole is anticipated to benefit from the rapid expansion of healthcare infrastructure and rising healthcare spending in emerging regions. Moreover, novel product launches by the key players boost the market. For instance, in January 2022, a new drug-eluting stent for below the knee (BTK) manufactured by Cook Medical was given Breakthrough Device classification by the US Food and Drug Administration (FDA). This innovation is meant to treat patients with persistent ischemia that poses a hazard to their limbs.

Peripheral Vascular Devices Market Report Highlights
  • Based on type, the peripheral stents segment held the market with the largest revenue share of 26.0% in 2023, owing to the improvements in stent technology and the rising adoption of less invasive procedures
  • Based on type, the peripheral accessories segment is anticipated to grow at the fastest CAGR over the forecast period. This is due to the presence of larger number of suppliers of peripheral accessories in the market as well as developing countries such as India and China offering low-cost supplies for these products. In addition to this, there is increasing demand for balloon inflation devices used for balloon angioplasty owing to the less risk and complications post-surgery, which is further driving the market growth
  • North America dominated the market with the revenue share of 39.52% in 2023. The market is driven by factors like the rising prevalence of cardiovascular disorders and the growing elderly population
  • Asia Pacific is anticipated to witness at the fastest CAGR over the forecast period. This is due to the increased public awareness of the need for prompt diagnosis and treatment, as well as improvements in peripheral vascular and cardiology technology in the region
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Regional scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Parent market analysis (Model 2)
1.7.4. Approach 2: Parent market analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market outlook
2.2. Segment outlook
2.2.1. Type outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Peripheral Vascular Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growing prevalence of PAD
3.2.1.2. Increasing clinical trials and studies
3.2.1.3. Novel product launch
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment and device
3.2.2.2. Product recalls
3.3. Peripheral Vascular Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Peripheral Vascular Devices Market: Type Estimates & Trend Analysis
4.1. Peripheral Vascular Devices Market: Type Dashboard
4.2. Peripheral Vascular Devices Market: Type Movement Analysis
4.3. Peripheral Vascular Devices Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Peripheral Stents
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Iliac Artery Stents
4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Femoral Artery Stents
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Carotid Artery Stents
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Renal Artery Stents
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Other Peripheral Stents
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. PTA Balloons
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Catheters
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.1.1. Angiography Catheters
4.6.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.1.2. Guiding Catheters
4.6.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6.1.3. IVUS/OCT Catheters
4.6.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Endovascular Aneurysm Repair Stent Grafts
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.1.1. Thoracic Endovascular Aneurysm Stent Grafts
4.7.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.1.2. Abdominal Endovascular Aneurysm Stent Grafts
4.7.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Plaque Modification Devices
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.1.1. Atherectomy Devices
4.8.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.1.2. Thrombectomy Devices
4.8.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Peripheral Accessories
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9.1.1. Guidewires
4.9.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9.1.2. Peripheral Vascular Closure Devices
4.9.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9.1.3. Balloon Inflation Devices
4.9.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9.1.4. Introducer Sheaths
4.9.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Inferior Vena Cava Filters
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.11. Hemodynamic Flow Alteration Devices
4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Peripheral Vascular Devices Market: Regional Estimates & Trend Analysis by Country, Type
5.1. Regional Dashboard
5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
5.3. North America
5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.3.2. U.S.
5.3.2.1. Key country dynamics
5.3.2.2. Regulatory framework/ reimbursement structure
5.3.2.3. Competitive scenario
5.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Canada
5.3.3.1. Key country dynamics
5.3.3.2. Regulatory framework/ reimbursement structure
5.3.3.3. Competitive scenario
5.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Europe
5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.4.2. UK
5.4.2.1. Key country dynamics
5.4.2.2. Regulatory framework/ reimbursement structure
5.4.2.3. Competitive scenario
5.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Germany
5.4.3.1. Key country dynamics
5.4.3.2. Regulatory framework/ reimbursement structure
5.4.3.3. Competitive scenario
5.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. France
5.4.4.1. Key country dynamics
5.4.4.2. Regulatory framework/ reimbursement structure
5.4.4.3. Competitive scenario
5.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Italy
5.4.5.1. Key country dynamics
5.4.5.2. Regulatory framework/ reimbursement structure
5.4.5.3. Competitive scenario
5.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Spain
5.4.6.1. Key country dynamics
5.4.6.2. Regulatory framework/ reimbursement structure
5.4.6.3. Competitive scenario
5.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Norway
5.4.7.1. Key country dynamics
5.4.7.2. Regulatory framework/ reimbursement structure
5.4.7.3. Competitive scenario
5.4.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Sweden
5.4.8.1. Key country dynamics
5.4.8.2. Regulatory framework/ reimbursement structure
5.4.8.3. Competitive scenario
5.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.4.9. Denmark
5.4.9.1. Key country dynamics
5.4.9.2. Regulatory framework/ reimbursement structure
5.4.9.3. Competitive scenario
5.4.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Asia Pacific
5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5.2. Japan
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. China
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
5.5.4. India
5.5.4.1. Key country dynamics
5.5.4.2. Regulatory framework/ reimbursement structure
5.5.4.3. Competitive scenario
5.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5. Australia
5.5.5.1. Key country dynamics
5.5.5.2. Regulatory framework/ reimbursement structure
5.5.5.3. Competitive scenario
5.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6. South Korea
5.5.6.1. Key country dynamics
5.5.6.2. Regulatory framework/ reimbursement structure
5.5.6.3. Competitive scenario
5.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.5.7. Thailand
5.5.7.1. Key country dynamics
5.5.7.2. Regulatory framework/ reimbursement structure
5.5.7.3. Competitive scenario
5.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Latin America
5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6.2. Brazil
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.6.3. Mexico
5.6.3.1. Key country dynamics
5.6.3.2. Regulatory framework/ reimbursement structure
5.6.3.3. Competitive scenario
5.6.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.6.4. Argentina
5.6.4.1. Key country dynamics
5.6.4.2. Regulatory framework/ reimbursement structure
5.6.4.3. Competitive scenario
5.6.4.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.7. MEA
5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7.2. South Africa
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. Saudi Arabia
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. UAE
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
5.7.5. Kuwait
5.7.5.1. Key country dynamics
5.7.5.2. Regulatory framework/ reimbursement structure
5.7.5.3. Competitive scenario
5.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.3. Vendor Landscape
6.3.1. List of key distributors and channel partners
6.3.2. Key customers
6.3.3. Key company market share analysis, 2023
6.3.4. Abbott
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Product benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Edward Lifesciences Corporation
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Product benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Medtronic
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Product benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Teleflex Incorporated
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Product benchmarking
6.3.7.4. Strategic initiatives
6.3.8. Boston Scientific Corporation
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Product benchmarking
6.3.8.4. Strategic initiatives
6.3.9. W. L. Gore & Associates, Inc.
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Product benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Boston Scientific Corporation
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Product benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Cook Group Inc.
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Product benchmarking
6.3.11.4. Strategic initiatives
6.3.12. Covidien
6.3.12.1. Company overview
6.3.12.2. Financial performance
6.3.12.3. Product benchmarking
6.3.12.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings